Back

The effect of glucagon-like peptide-1 receptor agonists on patients with heart failure with reduced ejection fraction

17 May 2025 (16:00 - 16:45)
Organised by: Logo
Congress Presentation Part of: Advances in GLP1-RAs, SGLT2 inhibitors and more Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Professor Zaza Iakobishvili

Holon Medical Center, Tel Aviv (Israel)

4 More presentations in this session

Presentation thumbnail
Impact of individual components of quadruple therapy in octagenerian heart failure patients: results from a real life data
Associate Professor I. Colluoglu (Izmir, TR)
Abstract Slides Video
Presentation thumbnail
Effects of SGLT-2 inhibitors on erythropoiesis and the associated cardio-renal benefits in patients with chronic heart failure
Ms S. Ugovsek (Ljubljana, SI)
Abstract Slides Video
Presentation thumbnail
Dapagliflozin for heart failure with reduced ejection fraction: early experience of treatment adherence and impact on patient-reported outcomes in EVOLUTION HF, a multinational, observational study
Professor J. Cardoso (Porto, PT)
Abstract Slides Video
Presentation thumbnail
Titration of sacubitril/valsartan in acute heart failure
Doctor S. Doi (Kawasaki, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Advances in GLP1-RAs, SGLT2 inhibitors and more

The Event

Event poster

Heart Failure 2025

17 May 2025 16:00 CET
You may be interested in
thumbnail
Congress Presentation
Advances in the treatment of HFrEF
thumbnail
Congress Presentation
Effects of glucagon like peptide 1 receptor agonist initiation in patients with heart failure and reduced ejection fraction and implantable cardiac devices
thumbnail
Congress Presentation
PRAISE-HFrEF: Glucagon-like peptide-1 receptor agonism in heart failure with reduced ejection fraction and obesity

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources